Mereo BioPharma Files 2023 Annual Report on Form 10-K

TL;DR

<b>Mereo BioPharma Group plc has submitted its annual 10-K filing for the fiscal year ended December 31, 2023, detailing its financial status and business operations.</b>

AI Summary

Mereo BioPharma Group plc (MREO) filed a Annual Report (10-K) with the SEC on March 27, 2024. Mereo BioPharma Group plc filed its 10-K report for the fiscal year ending December 31, 2023. The company is incorporated in Great Britain (GB) and operates in the Pharmaceutical Preparations industry (SIC 2834). Key dates mentioned include June 30, 2026, related to equity incentive plans. The filing references various financial instruments and plans, including warrants, convertible debt, restricted stock units, and employee stock options. Partnerships with Novartis, Ultragenyx, and Repronovo are noted, along with agreements like the 2015 Asset Purchase Agreement and Ultragenyx Collaboration and Licensing Agreement.

Why It Matters

For investors and stakeholders tracking Mereo BioPharma Group plc, this filing contains several important signals. This 10-K filing provides a comprehensive overview of Mereo BioPharma's financial performance, strategic partnerships, and operational activities for the fiscal year 2023, which is crucial for investors to assess the company's current standing and future prospects. The detailed information on financial instruments, equity plans, and significant agreements offers insights into the company's capital structure, executive compensation, and ongoing research and development efforts, impacting investment decisions.

Risk Assessment

Risk Level: medium — Mereo BioPharma Group plc shows moderate risk based on this filing. The filing is a standard 10-K, which typically contains a broad range of information. Specific risks are not detailed in the provided header data, but the nature of a pharmaceutical company implies inherent risks in drug development and market approval.

Analyst Insight

Review the full 10-K filing to understand the company's financial health, R&D pipeline progress, and any disclosed risks or strategic initiatives.

Key Numbers

• 2023-12-31 — Fiscal Year End (Period of report)
• 2024-03-27 — Filing Date (Date the 10-K was filed)
• 2026-06-30 — Plan Expiration/Maturity (Date related to equity incentive plans)

Key Players & Entities

• Mereo BioPharma Group plc (company) — Filer name
• Novartis (company) — Partnership mentioned
• Ultragenyx (company) — Partnership mentioned
• Repronovo (company) — Partnership mentioned
• Astrazeneca (company) — Mentioned in relation to a plan

FAQ

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K.
• 2024-03-27: Filing Date — Date the 10-K was officially submitted to the SEC.

Glossary

10-K

An annual report required by the U.S. Securities and Exchange Commission (SEC), which gives a comprehensive summary of a company's financial performance. (This filing provides the core financial and operational data for Mereo BioPharma for the fiscal year 2023.)

Warrant

A security that gives the holder the right, but not the obligation, to purchase a company's stock at a specific price until a certain expiration date. (Indicates potential future share dilution or capital raising activities for Mereo BioPharma.)

Convertible Debt

A type of debt security that can be converted into a predetermined amount of the issuer's equity at certain times during the debt's life. (Represents a potential source of equity financing for Mereo BioPharma, impacting its capital structure.)

Restricted Stock Units (RSUs)

A form of equity compensation awarded to employees, which vests over time or upon meeting certain conditions. (Reflects executive and employee compensation strategies at Mereo BioPharma.)

Key Financial Figures

• $ — ibody for potential treatment of OI; "$," "USD," "US
  quot; and "U.S. dollar" are to

Filing Documents

• mreo-20231231.htm (10-K) — 3874KB
• mreo-ex4_2.htm (EX-4.2) — 185KB
• mreo-ex10_30.htm (EX-10.30) — 399KB
• mreo-ex19_1.htm (EX-19.1) — 123KB
• mreo-ex23_1.htm (EX-23.1) — 4KB
• mreo-ex31_1.htm (EX-31.1) — 21KB
• mreo-ex31_2.htm (EX-31.2) — 21KB
• mreo-ex32_1.htm (EX-32.1) — 7KB
• mreo-ex32_2.htm (EX-32.2) — 7KB
• mreo-ex97_1.htm (EX-97.1) — 34KB
• img39675068_0.jpg (GRAPHIC) — 493KB
• 0000950170-24-037348.txt (&nbsp;) — 15158KB
• mreo-20231231.xsd (EX-101.SCH) — 1621KB
• mreo-20231231_htm.xml (XML) — 2268KB

Business

Business 5 Item 1A.

Risk Factors

Risk Factors 35 Item 1B. Unresolved Staff Comments 84 Item 1C. Cybersecurity 84 Item 2.

Properties

Properties 85 Item 3.

Legal Proceedings

Legal Proceedings 85 Item 4. Mine Safety Disclosures 86 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 87 Item 6. [Reserved] 87 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 88 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 98 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 98 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 99 Item 9A.

Controls and Procedures

Controls and Procedures 99 Item 9B. Other Information 100 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 100 PART III Item 10. Directors, Executive Officers and Corporate Governance 101 Item 11.

Executive Compensation

Executive Compensation 106 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 112 Item 13. Certain Relationships and Related Transactions, and Director Independence 113 Item 14. Principal Accountant Fees and Services 114 PART IV Item 15. Exhibit and Financial Statement Schedules 116 Item 16. Form 10-K Summary 119

Signatures

Signatures CERTAIN DEFINITIONS Unless otherwise indicated and except where the context otherwise requires, references in this Annual Report on Form 10-K (defined below) to: "AATD" are to alpha-1 antitrypsin deficiency, a lack of alpha 1 anti-trypsin protein, a protein made by the liver that's released into the bloodstream to protect the body from neutrophil serine proteases damaging the lungs; "Acumapimod" are to an oral p38 MAP kinase inhibitor for potential treatment of AECOPD; "Alvelestat" are to an oral neutrophil elastase inhibitor for potential treatment of AATD; "ADSs" are to our American Depositary Shares, each of which represents five ordinary shares of Mereo BioPharma Group plc; "ADRs" are to the American Depositary Receipts that evidence our ADSs; "AECOPD" are to acute exacerbation of chronic obstructive pulmonary disease; "BLA" are to Biologics License Application; "CMA" are to Conditional Marketing Authorization; "CMO" are to contract manufacturing organization; "COPD" are to chronic obstructive pulmonary disease, the name for a group of lung conditions that cause breathing difficulties; "CRO" are to contract research organization; "DTC" are to Depository Trust Company; "EMA" are to European Medicines Agency; "Etigilimab" are to an anti-TIGIT designed to activate the immune system through multiple mechanisms and enable anti-tumor activity; "Exchange Act" are to the United States Securities and Exchange Act of 1934; "Feng Biosciences" are to Feng Biosciences, Inc. In 2023, OncXerna Therapeutics, Inc. ("OncXerna") was renamed as Feng Biosciences, Inc.; "FDA" are to the United States Food and Drug Administration; "HH" are to hypogonadotropic hypogonadism, a condition in which the male testes or the female ovaries produce little or no sex hormones; "Leflutrozole" are to an oral aromatase inhibitor for potential treatment of male infertility associated with HH; "MAA" are to Marketing Authorization Application; "M

B usiness

Item 1. B usiness Overview We are a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. We have developed a portfolio of late-stage clinical product candidates. Our two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Setrusumab has received orphan designation for OI from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), PRIME designation from the EMA and has rare pediatric disease designation from the FDA. Alvelestat has received U.S. Orphan Drug Designation for the treatment of AATD and Fast Track designation for the treatment of AATD-LD. Our strategy is to selectively acquire and develop product candidates for rare diseases that have already received significant investment from large pharmaceutical and biotechnology companies and that have substantial pre-clinical, clinical and manufacturing data packages. Since our formation in March 2015, we have successfully executed on this strategy by acquiring six clinical-stage product candidates of which four were in rare diseases and oncology. Four of our six clinical-stage product candidates were acquired from large pharmaceutical companies and two were acquired in the Merger. We have successfully completed large, randomized Phase 2 clinical trials for four of our product candidates and the Phase 1b portion of a Phase 1b/2 for a fifth product candidate. Rare diseases represent an attractive development and, in some cases, commercialization opportunity for us since they typically have high unmet medical need and can utilize regulatory pathways that facilitate acceleration to approval and to the potential market. Development of products for rare diseases involve close collaboration with key opinion leaders and investigators, and close coordination with patient organizat

View Full Filing

View this 10-K filing on SEC EDGAR